Medical research and wellness trends, evidence-first.
Reported by Eli Okafor
New York announced its first measles death in 30 years. The CDC's public count still lists three deaths nationally, and a clinician alert on measles in pregnancy was reportedly blocked.
By Eli Okafor
· 3 min read
Accelerated approval rests on a 32-patient open-label trial in which 7 of 26 evaluable patients needed no surgery for a year. Confirmatory trials are required.
Two LITMUS papers graded blood and imaging tests against biopsy in fatty liver disease. Advanced scarring is now detectable with confidence, but inflammation and drug-trial entry still lean on biopsy.
An NEJM Evidence analysis finds incidence climbing in every age group up to 65 to 69, including heavily screened ones. The authors have not identified why, and one year of data is not a trend yet.
Dr. Shaggy of Veneer Lounge at The Star in Frisco worked five years as a dental hygienist before dental school. She says she still checks gum health, bone support and bite before any veneer discussion.
Frisco Body Contouring is a Frisco, Texas clinic led by nurse practitioner Jenessa McKray.
San Luis Obispo County says all five patients visited Brookshire Farms and three are children in serious condition. The county has not confirmed the farm as the source, and test results are pending.
A JAMA cohort of 385 donor pregnancies found most were uncomplicated and the absolute gap was 3.6 points. A smaller-baby signal is unconfirmed, and 63.9% of Ontario donors were related to recipients.
In the EMT2 trial of 418 patients, estimated five-year survival was 62.0% with EPA and 45.1% with placebo. Progression-free survival, the trial's main goal, did not differ significantly.
In a 144-patient randomized trial, a seven-mutation KRAS vaccine did not significantly delay recurrence. The strongest survival signals come from exploratory, within-arm comparisons.
A claims study of 48,658 US adults found 14.5 percent began at 1.0 mg a week or higher. They had a 25 percent higher risk of early discontinuation, but the design cannot show the dose was the cause.
Intismeran plus pembrolizumab lowered the risk of melanoma recurrence or death with a hazard ratio of 0.58 in 1,137 patients. Nothing was gained in the first six months, and overall survival is immature.
A UIC study of 8 adults and 14 children found pure cranberry juice cut plaque regrowth by 33 to 44 percent in a lab assay. The sweetened cocktail did nothing significant, and cavities were never counted.
A 190-person trial funded by the device maker found external counterpulsation outperformed a low-pressure sham on a cognitive scale. The sham arm gained more than half as much, and the percentages circulating online come from secondary reporting.
The October 19 accelerated approval covers about 3 percent of locally advanced rectal cancers. It rests on two small trials with no comparison group, and durability is not yet shown.
Fifty-three percent of the psilocybin group was in remission at six weeks versus 6 percent on niacin. At one year it was 53 percent versus 41 percent, and nearly every psilocybin recipient had guessed their assignment.
A secret-shopper study of commercial insurance directories in five states found errors on 55.6 percent of calls that reached a person. One attempt per listing and no voicemails make the 9.1 percent figure a floor.
A nationally representative JAMA Psychiatry survey of 2,009 adults found more self-reported cutting back among heavier drinkers. It had no comparison group, and the one small randomized trial found a narrower effect.
The Dexcom-sponsored CONNECT trial randomized 283 adults not on insulin. A smaller Alberta trial that stopped sensors after six weeks could not detect a lasting gap.
A Kaiser Permanente study is the first real-world look at a third RSV season after one Abrysvo dose. Protection fell each year, and one of its two outcomes is too imprecise to call.
